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Background. Polyglutamine expansion disorders are caused by an expansion of the polyglutamine (polyQ) tract in the disease
related protein, leading to severe neurodegeneration. All polyQ disorders are hallmarked by the presence of intracellular
aggregates containing the expanded protein in affected neurons. The polyQ disorder SpinoCerebellar Ataxia 1 (SCA1) is caused
by a polyQ-expansion in the ataxin-1 protein, which is thought to lead to nuclear aggregates. Methodology/Principal
Findings. Using advanced live cell fluorescence microscopy and a filter retardation assay we show that nuclear accumulations
formed by polyQ-expanded ataxin-1 do not resemble aggregates of other polyQ-expanded proteins. Instead of being static,
insoluble aggregates, nuclear accumulations formed by the polyQ-expanded ataxin-1 showed enhanced intracellular kinetics
as compared to wild-type ataxin-1. During mitosis, ataxin-1 accumulations redistributed equally among daughter cells, in
contrast to polyQ aggregates. Interestingly, polyQ expansion did not affect the nuclear-cytoplasmic shuttling of ataxin-1 as
proposed before. Conclusions/Significance. These results indicate that polyQ expansion does not necessarily lead to
aggregate formation, and that the enhanced kinetics may affect the nuclear function of ataxin-1. The unexpected findings for a
polyQ-expanded protein and their consequences for ongoing SCA1 research are discussed.
Citation: Krol HA, Krawczyk PM, Bosch KS, Aten JA, Hol EM, et al (2008) Polyglutamine Expansion Accelerates the Dynamics of Ataxin-1 and Does Not
Result in Aggregate Formation. PLoS ONE 3(1): e1503. doi:10.1371/journal.pone.0001503
INTRODUCTION
Polyglutamine (polyQ) expansion disorders include diseases such
as Huntington’s disease (HD), dentatorubropallidoluysian atrophy
(DRPLA), spinobulbar muscle atrophy (SBMA) and the spinocer-
ebellar ataxias (SCA) type 1, 2, 3, 6, 7 and 17. These polyQ
disorders are caused by an expansion of the CAG-trinucleotide
repeat region in the respective disease-related genes. Although the
different polyQ proteins are widely expressed in cells throughout
the brain, there is a high variability in the cell type loss in different
brain areas. In most polyQ disorders the disease becomes
manifested when the polyQ expansion exceeds 36–40 glutamines.
The length of the polyQ expansion is inversely correlated with the
age of onset of the disease. All polyQ disorders are dominantly
inherited and the general concept is that the disease is caused by a
toxic gain of function of the polyQ-expanded protein. Further-
more, commonly for all polyQ disorders, the affected cells show
intracellular aggregates containing the polyQ-expanded protein.
This aggregation is a result of the extended polyQ stretch in the
proteins. It is still unclear whether the aggregates are toxic for cells,
as a protective role has also been suggested [1–4].
SCA1 is a polyQ disorder caused by a glutamine expansion in
the protein ataxin-1, which results in selective loss of Purkinje cells
in the cerebellum, atrophy of specific brain stem neurons and
extensive loss of motor neurons in the spinal cord [5]. Patients
suffer from progressive loss of motor coordination, speech
impairment and problems with swallowing. In healthy individuals
the levels of ataxin-1 expression in the central nervous system is
two to four-fold of that in peripheral tissues [6]. The function of
ataxin-1 is still elusive. Wild-type ataxin-1 is a nuclear protein that
can shuttle between the nucleus and the cytoplasm [7]. In the
Purkinje cells and brain stem neurons, ataxin-1 is mainly present
in the nucleus and only to some extent in the cytoplasm. This is in
contrast with the localization of the protein in non-neuronal
tissues, where ataxin-1 is mainly in the cytoplasm [6,8–10]. This
suggests that the nuclear localization of ataxin-1 in Purkinje cells
may contribute to the selectivity of the disorder. Indeed,
transgenic mice expressing polyQ-expanded ataxin-1 with a
mutated nuclear localization signal did not develop the disease,
demonstrating that nuclear localization is critical for the
pathogenesis [3].
While the function of ataxin-1 is still elusive, it has been
suggested that ataxin-1 is involved in gene expression regulation,
as it can bind to RNA and interact with various transcription
factors [11–16]. Ataxin-1 contains an AXH (Ataxin-1 and HMG-
box protein 1) domain that has been shown to interact with other
proteins and RNA and that has been implicated to play a role in
transcriptional repression [12,16–20]. In addition, ataxin-1 has a
self associating region spanning the amino acids 570 to 605 of the
wild-type protein. This region overlaps partly with the AXH
domain [19]. The presence of nuclear aggregates in the
cerebellum of SCA1 patients has led to the assumption that the
polyQ-expansion causes ataxin-1 to misfold and form intranuclear
aggregates. Not only may these aggregates lead to neuronal
toxicity, polyQ-expansion may also alter the normal function of
ataxin-1, or lead to the loss of nucleocytoplasmic shuttling ability.
While aggregates composed of polyQ-expanded proteins are
generally static structures comprised of tightly aggregated proteins,
we state that this assumption needs to be reevaluated in the case of
SCA1.
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PLoS ONE | www.plosone.org 1 January 2008 | Issue 1 | e1503Here we show that the kinetics of nuclear polyQ-expanded
ataxin-1 accumulations are very different from other polyQ
proteins. Both wildtype (Atx1[Q2]GFP) and polyQ-expanded
(Atx1[85Q]GFP) accumulations turned out to be soluble, whereas
other polyQ-GFP aggregates form insoluble structures. In
addition, mitotic cells redistributed the nuclear accumulations of
polyQ-expanded ataxin-1 proteins to both daughter cells, whereas
‘true’ polyQ aggregates were all trans-located to one daughter cell.
In contrast to an earlier report [7], the polyQ-expansion did not
affect shuttling of ataxin-1 between the nucleus and cytoplasm.
Surprisingly, a longer polyQ-expansion led to an increase in speed
of exchange of ataxin-1 between the nuclear accumulations and
the free nuclear pool. In addition, we observed that the ataxin-1
accumulations were mobile and frequently fused with each other,
and polyQ-expansion led to an increase in both mobility and
fusion of the nuclear accumulations.
RESULTS
PolyQ-expanded ataxin-1 does not form insoluble
aggregates
PolyQ disorders show accumulation of polyQ-expanded proteins
into a single cytoplasmic or nuclear aggregate. In agreement with
data published previously [13,21] our experiments demonstrated
that ataxin-1 is mostly accumulating into multiple nuclear
accumulations and this process is independent of the length of
the polyQ expansion (Fig 1A). To compare the distribution and
aggregate formation of ataxin-1 to a variety of different polyQ-
expanded proteins we transfected Cos-7 cells with different polyQ
proteins tagged with green fluorescent protein (GFP), to enable
visualization in living cells. Cos-7 cells were chosen since they have
a low expression level of endogenous ataxin-1 [8]. This minimizes
interactions between the transfected ataxin-1 fusion proteins and
Figure 1. Nuclear ataxin-1 accumulations do not resemble aggregates formed by other disease-related polyglutamine-expanded proteins. (A).
Live cell images of wild-type and polyQ-expanded ataxin-1 (Atx1[Q2]GFP and Atx1[Q85]GFP) and polyglutamine-expanded proteins androgen
receptor (AR[Q112]GFP), huntingtin exon-1 (Htt[Q103]GFP), NLS[Q64]GFP and Q65-GPF in Cos7 cells. (B). Filtertrap assay of celllysates of Cos7 cells
expressing Atx1[Q2]GFP, Atx1[Q85]GFP and NLS[Q64]GFP, 24, 48 and 72 hr after transfection (upper panel) and of Cos7 cells expressing
AR[Q112]GFP, Q65-GFP and Htt[Q103]GFP 24 hours after transfection (lower panel). Sizebar=1 mm.
doi:10.1371/journal.pone.0001503.g001
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additional effect on the attaxin-1 aggregate formation. Next to the
wildtype ataxin-1 (Atx1[2Q]GFP) and the polyQ-expanded ataxin-1
(Atx1[85Q]GFP), two disease-related polyQ-expanded fusion pro-
teins were used, i.e. the truncated androgen receptor
(AR[Q112]GFP) and huntingtin exon1 (Htt[Q103]GFP) which
are both aggregation-prone (Fig 1A). We also expressed a pure
polyQ-tract fused to GFP (Q65-GFP) and a polyQ-GFP fused to a
nuclear localization signal (NLS[Q64]GFP). These fusion proteins
are also aggregation-prone due to a similar polyQ-expansion. The
NLS signal targets the protein to the nucleus, which mimics ataxin-1
polyQ localization. When cells were analyzed by Confocal Laser
Scanning Microscopy, all polyQ-expanded proteins formed irregu-
larly shaped intracellular aggregates within 24 hours after transfec-
tion, with exception of Atx1[85Q]GFP and Atx1[2Q]GFP which
formed multiple nuclear accumulations (Fig 1A). The formation of
multiplenuclearaccumulations of Atx1[2Q]GFPhasbeendescribed
before [13,21]. The distinct pattern of the formation of multiple
nuclear accumulations is probably due to features of the ataxin-1
protein, since nuclear polyQ-expanded GFP (NLS[Q64]GFP)
resulted in a single nuclear aggregate which increased in size in
time due to sequestering of newly synthesized polyQ-GFP proteins,
similar as observed with other polyQ-expanded proteins. This main
difference between Atx1[85Q]GFP and NLS[Q64]GFP was
maintained up to 72 hours after transfection.
As polyQ-protein aggregates form insoluble inclusions we
examined whether the distinct difference in distribution between
ataxin-1 and other polyQ proteins is also reflected by a difference
in the solubility of the aggregates. By using a filter retardation
assay, SDS-insoluble aggregates can be detected and quantified on
a membrane while the remaining cell lysate passes through [22].
The solubility of both the Atx1[Q2]GFP and Atx1[85Q]GFP
ataxin-1 was compared to NLS[Q64]GFP at three different time
points after transfection (24, 48 and 72 hours, Fig 1B). At these
timepoints most cells contained both small and large accumula-
tions of Atx1[2Q]GFP, Atx1[85Q]GFP and NLS[Q64]GFP.
Aggregates formed by the truncated androgen receptor
(AR[Q112]GFP), Q65-GFP and huntingtin exon-1
(Htt[Q103]GFP) were already present after 24 hours and also
varied in size from small to large. Figure 1B clearly shows that the
ataxin-1 accumulations are soluble, whereas all other polyQ
aggregates were trapped on the filter. This suggests that nuclear
accumulations consisting of polyQ-expanded ataxin-1 cannot be
defined as aggregates, as ataxin-1 accumulations are soluble and
not sequestered into a single aggregate as generally observed in
polyQ disorders. Instead of calling them aggregates, the term
nuclear accumulations will now be used for these soluble
structures.
PolyQ expansion increases nuclear dynamics of
ataxin-1
Since polyQ aggregates are generally static structures character-
ized by a low on/off rate of the aggregated proteins, we next
examined whether the length of the polyQ-expansion would
affect the kinetics of the nuclear ataxin-1 accumulations. To
compare the kinetics in a background of low endogenous ataxin-
1 levels we transfected both Atx1[Q2]GFP and Atx1[Q85]GFP
into Cos-7 cells and analyzed formed nuclear accumulations by
confocal microscopy. Both Atx1[Q2]GFP and Atx1[Q85]GFP
formed nuclear accumulations of various sizes, and we observed
movement and fusion of all types of nuclear accumulations in
time (Fig 2A, supplementary Movie S1). We next investigated
whether the polyQ length might affect the duration of the fusion
in the cell nucleus by determining the time needed for a
complete fusion event. Time-lapse imaging monitored the fusion
process of similarly sized nuclear ataxin-1 accumulations. As
shown in Figure 2B and Movie S1 in the supplementary
material, the fusion of two nuclear Atx1[Q85]GFP accumula-
tions is faster than of two similarly sized Atx1[Q2]GFP
accumulations (P=0.0019). We analyzed respectively 9 and 11
fusion events for Atx1[Q2]GFP and Atx1[Q85]GFP in individual
cells and we observed that the fusion of the nuclear
Atx1[Q2]GFP accumulations was finished in a time between
172 and 670 seconds (median=342 seconds) and of the
Atx1[Q85]GFP accumulations between 80 and 340 seconds
(median=125 seconds). This suggests that the nuclear accumu-
lations of Atx1[Q85]GFP are more dynamic then Atx1[Q2]GFP,
and that polyQ expansion accelerates the fusion between nuclear
ataxin-1 accumulations. In addition we studied whether the
Atx1[Q2]GFP and Atx1[Q85]GFP accumulations have different
mobilities in the nucleus. We compared the mobility of equally
sized accumulations of Atx1[Q2]GFP or Atx1[Q85]GFP in the
nucleus 24 hours after transfection. The mobility of 93 nuclear
Atx1[Q2]GFP accumulations, measured in 12 individual cells,
was compared to 128 Atx1[Q85]GFP accumulations in 16
individual cells. The mean square displacement of these
accumulations has been calculated after each time point. The
presence of a polyQ expansion resulted in an increased mobility
of the nuclear accumulations in the nucleus (Fig 2C). The
accelerated fusion speed and mobility of Atx1[Q85]GFP
contrasts with the general view that polyQ aggregates are static,
immobile structures composed of irreversibly trapped polyQ
proteins.
To examine the on/off rate of nuclear ataxin-1 accumulations
we performed Fluorescence Recovery after Photobleaching
(FRAP) experiments to determine the exchange of ataxin-1
present between accumulations and the nuclear environment.
Using FRAP, irreversible photobleaching leads to permanent loss
of the fluorescence of the selected nuclear ataxin-1 accumulation,
and fluorescence recovery can only occur when bleached ataxin-1
is replaced by fluorescent ataxin-1 from other nuclear accumula-
tions or the free pool. The time needed for the recovery of
fluorescence is therefore representative for the rate of exchange
between the bleached nuclear accumulation, the surrounding
Atx1-GFP fluorescent accumulations and the nuclear pool of
Atx1-GFP. Surprisingly, when measuring the t1/2 (which is the
time point where the fluorescence has recovered to 50% of its
original fluorescence intensity level), we found that fluorescence of
the Atx1[Q85]GFP accumulations recovered much faster than
Atx1[Q2]GFP (Fig 2D). In addition, we measured differences in
the recovery of the small and large nuclear accumulations,
since we anticipated that larger accumulations would show a lower
exchange due to the reduction in surface/volume ratio. The
t1/2 of small Atx1[Q85]GFP accumulations (median=48 seconds)
was significantly lower than the t1/2 of small Atx1[Q2]GFP
accumulations (median=102.4 seconds) (P=0.001), measured
in respectively 8 and 11 bleaching experiments in individual
cells. In addition, the t1/2 of large Atx1[Q85]GFP accumula-
tions (median=67.2 seconds) was also significantly lower than
Atx1[Q2]GFP accumulations (median=183.6 seconds) (P=
0.013), measured in respectively 7 and 9 experiments. We
observed no difference in size between the immobile fractions
of the nuclear accumulations formed by either Atx1[Q2]GFP
or Atx1[Q85]GFP (data not shown). These data indicate that
polyQ-expansion enhances the kinetics of ataxin-1, leading to less
stable structures, which is also suggested by the accelerated fusion
speed.
Ataxin-1 Nuclear Bodies
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symmetrically during cell division
Cells containing polyglutamine aggregates are still able to enter
mitosis [23] (and unpublished observation). Interestingly, when cells
contained multiple aggregates, these aggregates were always
distributed to only one of the daughter cells, whereas the other
daughter cell was free of any aggregate. We therefore examined
whether polyQ-expanded ataxin-1 accumulations are also asym-
metrically divided during mitosis, by following the nuclear
accumulations in mitotic cells that expressed either Q65-GFP,
Atx1[Q2]GFP or Atx1[Q85]GFP, using automated time-lapse
fluorescence imaging. Indeed, mitotic cells containing multiple
polyQ nuclear aggregates formed by Q65-GFP showed asymmet-
rical separation of aggregates to only one daughter cell (Fig 3A). In
contrast, cells containing multiple nuclear accumulations formed by
either Atx1[Q2]GFP or Atx1[Q85]GFP distributed ataxin-1 to both
daughter cells, regardless of polyQ expansion (Fig 3B,C). Note that
most nuclear accumulations fuse into large accumulations shortly
before entering mitosis, while right after cell division, both daughter
cells again contain multiple small nuclear accumulations.
PolyQ expansion does not affect ataxin-1 nuclear
shuttling
As wild-type ataxin-1 can shuttle between the nucleus and the
cytoplasm of a cell, it has been suggested that ataxin-1 is involved in
RNA binding and transport to the cellular periphery [7]. This
transport may be abolished in SCA1, as polyQ expansion hampers
the nuclear export ofataxin-1[7]. It shouldhowever be noted that in
this study small wild-type ataxin-1 nuclear accumulations were
compared to large polyQ-expanded ataxin-1 nuclear accumulations.
As we showed that large accumulations of both polyQ-expanded
Atx1[Q85]GFP and wildtype Atx1[Q2]GFP have a lower recovery
rate when compared to small accumulations this might have limited
the exitof freeataxin-1from the nucleus.WealsoobservedthatCos-
7 cells expressing either Atx1[Q2]GFP or Atx1[Q85]GFP showed
cytoplasmic presence of the protein, either diffuse or in body-like
structures, independent of the length of the polyQ expansion
(Fig 4A). The presence of cytoplasmic polyQ-expanded ataxin-1 is
not limited to Cos-7 cells, as cultured neuroblastoma cells such as
SH-SY5Y and N2A neuroblastoma cells (Fig 4A) as well as
U343MG astrocytoma cells (data not shown) showed cytoplasmic
presence andmovement of ataxin-1accumulations.The cytoplasmic
r
Figure 2. Polyglutamine expansion accelerates ataxin-1 dynamics.
(A). Atx1[Q2]GFP and Atx1[Q85]GFP form similarly sized nuclear
accumulations including small nuclear accumulations (upper panel)
and large nuclear accumulations (lower panel). (B). PolyQ expansion
enhances ataxin-1 nuclear accumulation fusion speed. Pictures 1–5
show fusion of two Atx1[Q85]GFP nuclear accumulations within
150 seconds. The fusion speed of Atx1[85Q]GFP nuclear accumulations
is faster than of similarly sized Atx1[Q2]GFP nuclear accumulations
(lower panel, n=9 resp. 11). Data have been tested non-parametrically
(**P,0.005). (C). Increased mobility of Atx1[Q85]GFP over Atx1[Q2]GFP
nuclear accumulations 24 hours after transfection. The Y-axis depicts
the average mean square displacement (MSD) of 93 Atx1[Q2]GFP
nuclear accumulations and 128 similarly sized Atx1[Q85]GFP nuclear
accumulations. (D). Atx1[Q85]GFP nuclear accumulations have a higher
on/off rate than Atx1[Q2]GFP nuclear accumulations. FRAP live cell
experiments were performed 24 hr after transfection. Small and large
nuclear accumulations have been analyzed separately. Half-time
recovery data have been tested non-parametrically (**P,0.005,
*P,0.05). Sizebar=1 mm.
doi:10.1371/journal.pone.0001503.g002
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and shuttling to cytoplasmic domains [7]. To test whether polyQ-
expansion limits the nuclear-cytoplasmic shuttling of ataxin-1, we
performed a nucleocytoplasmic shuttling assay with Atx1[Q2]GFP
and Atx1[Q85]GFP transfected in Cos-7 cells. To measure the
nuclear shuttling, we performed FRAP analysis on cells containing
two nuclei (bikaryons) by photobleaching all fluorescence except for
one ataxin-1 nucleus and visualized the exchange and shuttling of
GFP-tagged ataxin-1 by imaging the increase of fluorescence in the
bleached nucleus. These experiments were performed in the
presence of the translation inhibitor cycloheximide to prevent
fluorescence recovery due to de novo synthesis of ataxin-1. We
distinguished between cells having either only small or large nuclear
ataxin-1 accumulations. Cells having only free nuclear ataxin-1
distribution or ataxin-1 present in small nuclear accumulations
showed recovery of fluorescence in the bleached nucleus within
30 minutes after bleaching, independent of the length of a polyQ
expansion (Fig 4B,C, upper panel). However, the bikaryons with
large nuclear ataxin-1 accumulations did not show any recovery
within this time span. This observation was independent of the
length of the polyQ tract (Fig 4B,C lower panel). Taken together,
these data show that the shuttling of ataxin-1 only occurs when the
protein is diffusely dispersed in the nucleoplasm or when the protein
is present in small nuclear accumulations. More importantly, the
ability of ataxin-1 to shuttle from the nucleus is not affected by the
length of the polyQ expansion.
DISCUSSION
PolyQ disorders are characterized by the presence of insoluble,
intracellular aggregates initiated by the respective polyQ-expanded
proteins, and these aggregates are also present when the polyQ
expansion is fused to non disease-related proteins (e.g. Q65-GFP).
Nuclear aggregates are present in neurons of several brain areas in
transgenicmiceexpressinganexpansionof146glutaminesfusedtoa
non disease-related protein [24]. While processes like autophagy
may clear the cytoplasm from polyQ aggregates, the nucleus seems
particularly sensitive since in all polyQ diseases the aggregates have
been primarily found inthe nuclei of patient material tissue [25]. It is
therefore not surprising that SCA1 is often categorized as one of the
polyQ disordersdue to the presenceofnuclear aggregates.However,
various reports have shown that polyQ expansion is not the only
domain which can induce ataxin-1 accumulation as the self
associating region and two other domains seem to be involved in
ataxin-1self-association [12,19]. Accordingly,wild-type ataxin-1can
also form similar nuclear structures, and deletion of the self
associating region prevents nuclear accumulation of polyQ-expand-
ed ataxin-1 in COS cells and transgenic mice [3,10]. This is in
contradiction with findings showing that polyQ expansion leads to
inclusion formation in SCA1.
We observed that nuclear polyQ-expanded ataxin-1 accumu-
lations could not be detected by a filter retardation essay, whereas
other polyglutamine aggregating proteins where clearly insoluble
(including nuclear polyQ-GFP proteins). The non-static behavior
of nuclear Atx1[Q85]GFP accumulations was also shown by their
ability to move and fuse within the nucleus, with a surprising
increase in the fusion speed and on/off rates as compared to wild-
type nuclear ataxin-1 (Atx1[Q2]GFP) accumulations. The en-
hanced fusion could also result in a slightly higher amount of large
nuclear accumulations in time in Atx1[Q85]GFP cells [21]. The
enhanced on/off rate of polyQ-expanded ataxin-1 is different from
earlier observations by Stenoien and colleagues, who showed that
polyQ expansion of ataxin-1 leads to reduced exchange within
nuclear accumulations [21]. Since ataxin-1 has been shown to
associate with the nuclear matrix [8], structures incorporating
polyQ-expanded ataxin-1 may be less stably associated with the
matrix then the wild-type ataxin-1, which might in turn lead to an
increase of their mobility. However the nuclear matrix is a
structure that is not clearly defined and it might be more
appropriate to suggest that ataxin-1 associates with the nuclear
scaffold. It has been suggested that ataxin-1 is present in a
transcription/RNA processing complex [7,18] whose functionality
is lost upon transcription inhibition. An example is the known
complex of ataxin-1, RORa, a transcription factor critical for
cerebellar development, and tip60, a co-activator of RORa
Figure 3. Nuclear ataxin-1 accumulations distribute symmetrically to daughter cells during cell division. Representative series of images showing
cell division of a cell containing fluorescent aggregates or nuclear accumulations. (A). Asymmetric distribution of Q65-GFP aggregates in time. Arrows
indicate the two daughter cells. (B). Symmetric distribution of Atx1[Q2]GFP nuclear accumulations during cell division. Nuclear accumulations fuse
prior to division. After division both daughter cells contain cytoplasmic accumulations and later nuclear accumulations. (C). Symmetric distribution of
Atx1[Q85]GFP nuclear accumulations during cell division. Time is indicated in minutes. Sizebar=1 mm.
doi:10.1371/journal.pone.0001503.g003
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self-association of ataxin-1, but may also disturb the interaction
with proteins such as RORa and tip60, resulting in alteration of
transcriptional activity of several proteins and downregulation of
important proteins [28]. The observed decrease in stable complex
interactions of polyQ-expanded ataxin-1 containing nuclear
accumulations might therefore affect its regulatory function.
Besides enhanced kinetics and solubility, a third major
difference between polyQ-expanded ataxin-1 and other polyQ
proteins was the separation of aggregates during cell division. Cells
containing multiple polyQ aggregates are viable enough to enter
mitosis, and by yet undefined mechanism all aggregates segregate
into one daughter cell. While it is attractive to think that this might
be a mechanism allowing separation of harmful proteins into one
cell and leaving the other free of aggregates, it is of less importance
for neurons, most of which are post-mitotic. In contrast to the
asymmetrically dividing polyQ aggregates, nuclear polyQ ataxin-1
accumulations are redistributed equally among the daughter cells.
They fuse into large accumulations prior to the actual M phase,
and during the actual division the accumulations rapidly dissociate
into a diffuse nuclear distribution. As the appearance of small
accumulations can be observed soon after cell division, this
mechanism may guarantee equal distribution of these proteins to
both daughter cells. This phenomenon also occurs in case of
specific cytoplasmic organelles but also the nucleoli (which also has
a function in local transcription and RNA binding), resulting in
equal redistribution to both daughter cells [29]. It also supports
our model that nuclear accumulations formed by ataxin-1
resemble functional complexes and not aggregates. Therefore we
suggest that ataxin-1 nuclear bodies should be a better definition
than aggregates, inclusion bodies or accumulations
Shortly after mitosis we observed a rapid re-formation of
multiple ataxin-1 nuclear bodies that subsequently localize to the
newly formed nucleus. The rapid ataxin-1 dynamics and
Figure 4. Polyglutamine expansion does not affect ataxin-1 shuttling between the nucleus and the cytoplasm. (A). Cos-7 cells and N2A and
differentiated SH-SY5Y neuronal cells contain cytoplasmic accumulations of both Atx1[Q2]GFP and Atx1[Q85]GFP. (B). Representative
nucleocytoplasmic shuttling assay in a Cos-7 bikaryon with small and large Atx1[Q2]GFP nuclear accumulations. Shuttling to the bleached nucleus
is only observed when small nuclear accumulations are present. (C). Atx1[Q85]GFP can shuttle between nucleus and cytoplasm when bikaryons of
Cos-7 cell contain small nuclear accumulations. When large nuclear accumulations are present there is no nucleocytoplasmic shuttling of either
Atx1[Q2]GFP or Atx1[Q85]GFP. The bleached region is indicated in white. Sizebar=1 mm.
doi:10.1371/journal.pone.0001503.g004
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ataxin-1 is able to shuttle through the nuclear pore complex and is
in contrast by findings from Irwin and collegues [7]. In this study
the nucleocytoplasmic shuttling capability of wild type ataxin-1 in
cells containing small nuclear bodies was compared with cells
containing only large polyQ-expanded ataxin-1 nuclear bodies.
Since the size of the nuclear bodies affects on/off ratios and
therefore the amount of free ataxin-1, we compared similarly-sized
nuclear bodies between Atx1[Q2]GFP and Atx1]Q85]GFP
expressing cells. Interestingly, if only large nuclear bodies are
present there is no nucleocytoplasmic shuttling of either ataxin-1
protein. In the case of free nucleoplasmic distribution or only small
nuclear bodies, shuttling is not impaired by polyQ expansion. To
unravel SCA1 disease it will be important to understand the
nature of these nuclear bodies and to examine their composition
and function in both the nucleus and cytoplasm But if the polyQ
expansion does not induce aggregation or impair nuclear shuttling,
what may be affected in SCA1? Ataxin-1 is involved in multiple
pathways as suggested previously and each of these might
contribute to SCA1 pathogenesis [26]. PolyQ-expanded ataxin-1
might play its role at the transcriptional level and alter the
transcription of genes important for Purkinje cells [11,26,28]. In
addition polyQ-expanded ataxin-1 could be involved in post-
transcriptional processes such as mRNA splicing through its
interaction with polyglutamine-tract-binding protein 1 (PQBP1)
[14], a protein that has been shown to interact with the splicing
factor SIPP1 [30]. PolyQ expansion of ataxin-1 also influences its
binding to RNA [18] and in this manner could alter its suggested
role in nucleocytoplasmic shuttling of mRNA [7], a process that is
very important for local translation of proteins in neurons.
MATERIALS AND METHODS
DNA constructs
Q65-GFP was generated using Ub-M-GFP-Q65 as a template
(kindly provided by Nico Dantuma, Stockholm, Sweden) using
primers flanking the polyQ stretch (forward: CCGGAATTCAC-
CATGGAGTACACACCTCCCGGCGCCAGTTT with EcoRI
site and reverse: GGATCCCGGGCCCCTCCTGGGGCTAG-
TCTCTTGCTG with ApaI site) and subsequent ligation into
EGFP-N3 vector (Clontech, Palo Alto, CA). Htt[Q103]GFP was
kindly provided by Ron Kopito, Stanford, California.
AR[Q112]GFP contains a truncated version of the androgen
receptor tagged with GFP (kindly provided by Paul Taylor,
Philadelphia, Pennsylvania). The NLS[Q64]GFP contains a
nuclear localization signal (NLS) to target the protein to the
nucleus (kindly provided by Itaru Toyoshima, Akita, Japan).
Atx1Q2]GFP and Atx1[Q85]GFP contain full length ataxin-1
cloned into a pEGFP-C2 vector (kindly provided by Huda Zoghbi,
Houston, Texas).
Cell culture and transfection
Cos7, SH-SY5Y and N2A cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum and 5% penicillin (100 U/ml), streptomycin
(100 mg/ml) and glutamine (100 mg/ml). U343MG astrocytomas
cells were cultured in DMEM (high glucose) and HAM F10 (1:1)
supplemented with 10% fetal bovine serum, 5% penicillin and
100 U/ml streptomycin. Cells were maintained at 37uCi na n
atmosphere of 5% CO2. For live cell microscopy 0.2610
26 cells
were plated on glass coverslips (24 mm; Fisher scientific,
Braunsweg, Germany) in a 6 well plate and transfected with
DNA plasmids after 24 hours using Lipofectamine 2000 transfec-
tion reagent according to manufacturer’s instructions (Invitrogen)
for Cos-7, N2A and U343MG astrocytoma cells. SH-SY5Y cells
were transfected using dreamfect gold (OZ Biosciences). Retinoic
acid (Sigma R 2625, final concentration 10 mM) was added to the
SH-SY5Y culture medium for 3 days to differentiate them. For
fixation 4% paraformaldehyde in PBS was used.
Filter retardation assay
Filter retardation assay was performed as described before [22].
Briefly, cell lysates were incubated for 30 minutes on ice and
centrifuged at 14,000 rpm for 15 minutes at 4uC. Pellets
containing the insoluble material and aggregates were resuspended
in benzonase buffer (1 mM MgCl2, 50 mM Tris-HCl; pH 8.0) and
incubated for 1 hour at 37uC with 1 ml benzonase (100,000 units/
vial (Merck, Darmstadt, Germany). Incubations were terminated
by adding 100 ml 2x termination buffer (40 mM EDTA, 4% SDS,
100 mM DTT). Equal amounts of protein extracts were diluted in
200 ml 2% SDS and filtered on a dot-blot filtration unit through a
cellulose acetate membrane (Schleicher and Schuell, 0.2-mm pore
size) that has been pre-equilibrated with 2% SDS. Filters were
washed twice with 200 ml 0.1%SDS and GFP fluorescence was
measured by using the LAS-3000 (Fujifilm).
Confocal Laser Scanning Microscopy (CLSM) and
Fluorescence Recovery After Photo-bleaching
(FRAP) analysis
Transfected cells were categorized by the size of the nuclear
accumulations: small (#1 mm diameter) and large ($2.5 mmsize).
FRAP analysis was performed using a Leica Sp2 CLSM adapted for
living cell analysis using a 63x oil immersion objective. A selected
ataxin-1 accumulation was repeatedly bleached in 10 frames at
maximum laser power, resulting ina reduction offluorescence to less
than 10% of the initial value. Fluorescence recovery was measured
by time-lapse imaging for 10 minutes post bleaching. Intranuclear
mobility of the nuclear accumulations in time was corrected for
overall movement of the nucleus by a custom-written software based
on Matlab (Mathworks, Inc., USA) DipImage and IterativeClosest
Point algorithm (Krawczyk, P in press).
Nucleocytoplasmic transport assay
Cells were incubated with cycloheximide (final concentration
200 mM) for 15 minutes prior to cell fusion, which was performed
by washing the cells with PBS, incubating them in 50% (w/v)
polyethylene glycol 1500 (Roche Molecular Biochemicals) for 2 min,
and rinsing with PBS. Cells were then incubated for 20 minutes in
the cellculture mediumcontaining 100 mg/ml cycloheximidebefore
analysis by CLSM. During the experiment the cells were incubated
inthe samecellculturemediumincluding cycloheximide.FRAP was
performed on a laser scanning confocal microscope (Leica Sp2
CLSM) by photobleaching a region surrounding the bikaryon but
one nucleus. Recovery of fluorescence in the bleached nucleus was
monitored in time and compared to the fluorescence intensity of the
second nucleus in the bikaryon.
Life cell imaging
Time lapse movies were performed using a Leica (DM-IRBE)
inverted microscope and a 63x oil immersion objective enclosed in a
37uC incubator with atmosphere of 5% CO2.I m a g e sw e r ec r e a t e d
using a GFP filter set (Leica c1) for GFP excitation. For the analysis
of accumulation behavior during cell division fluorescent and phase
contrast images have been taken every 10 minutes. For the analysis
ofaccumulationmobility,3-D, time-lapse moviesofnuclearataxin-1
accumulations, acquired every 2 min have been deconvolved and
Ataxin-1 Nuclear Bodies
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squared displacement (MSD) of the nuclear accumulations during
30 minutes was calculated. For the analysis of accumulation fusion,
2-D images were acquired every 2 seconds. Fusion was calculated as
a time between touching of two fusing nuclear accumulations and
rounding of the resulting accumulation.
SUPPORTING INFORMATION
Movie S1 Fusion of nuclear ataxin-1 accumulations. Time lapse
movie of nuclear Atx1[Q85]GFP accumulations fusion. Time
between two frames is 20 seconds.
Found at: doi:10.1371/journal.pone.0001503.s001 (1.55 MB AVI)
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